B Lymphocyte Depletion Therapy in Autoimmune Disorders: Chasing Trojan Horses

2006 ◽  
pp. 291-311 ◽  
Author(s):  
Jonathan C. W. Edwards ◽  
Geraldine Cambridge ◽  
Maria J. Leandro
2002 ◽  
Vol 30 (4) ◽  
pp. 824-828 ◽  
Author(s):  
J. C. W. Edwards ◽  
M.J. Leandro ◽  
G. Cambridge

B-lymphocyte depletion therapy is being explored in a wide range of autoimmune disorders. In many, there is early evidence for efficacy, and immunosuppression has not been a major problem. The mechanism of action is unclear, but appears to be consistent with the lowering of autoantibody levels, where relevant antibodies are quantifiable. An interesting finding is the persistence of clinical improvement for periods of 1 year or more after B-lymphocyte return, which supports the concept that stochastic generation of rare pathogenic B-lymphocyte subsets may be a rate-limiting step in pathogenesis.


2007 ◽  
Vol 92 (10) ◽  
pp. 3762-3763 ◽  
Author(s):  
Daniel El Fassi ◽  
Ole Clemmensen ◽  
Claus H. Nielsen ◽  
Rona Z. Silkiss ◽  
Laszlo Hegedüs

2009 ◽  
Vol 361 (22) ◽  
pp. 2143-2152 ◽  
Author(s):  
Mark D. Pescovitz ◽  
Carla J. Greenbaum ◽  
Heidi Krause-Steinrauf ◽  
Dorothy J. Becker ◽  
Stephen E. Gitelman ◽  
...  

Cytotherapy ◽  
2017 ◽  
Vol 19 (5) ◽  
pp. S76-S77
Author(s):  
E. Haastrup ◽  
M. Ifversen ◽  
C. Heilmann ◽  
A. Fischer-Nielsen

2007 ◽  
Vol 92 (5) ◽  
pp. 1769-1772 ◽  
Author(s):  
Daniel El Fassi ◽  
Claus H. Nielsen ◽  
Steen J. Bonnema ◽  
Hans C. Hasselbalch ◽  
Laszlo Hegedüs

Sign in / Sign up

Export Citation Format

Share Document